• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ALERE SAN DIEGO, INC. ALERE HCG10/20 DEVICE (SERUM/URINE) 40T; VISUAL, PREGNANCY HCG, PRESCRIPTION USE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ALERE SAN DIEGO, INC. ALERE HCG10/20 DEVICE (SERUM/URINE) 40T; VISUAL, PREGNANCY HCG, PRESCRIPTION USE Back to Search Results
Model Number FHC-A202
Medical Device Problem Code False Positive Result (1227)
Health Effect - Clinical Code No Clinical Signs, Symptoms or Conditions (4582)
Date of Event 05/22/2024
Type of Reportable Event Malfunction
Event or Problem Description
The customer reported receiving false positive hcg results while using alere hcg strip urine tests for two patients.The first patient presented on (b)(6) 2024 for hcg testing, prior to nexplanon placement for contraception.The patient provided a fresh urine sample.Three drops of urine were applied to the device and the results were read at 4 minutes yielding a positive hcg result.Confirmatory blood hcg testing was performed which yielded a negative result.No adverse events were reported.
 
Additional Manufacturer Narrative
Results pending completion of the investigation.
 
Event or Problem Description
The customer reported receiving false positive hcg results while using alere hcg strip urine tests for two patients.The first patient presented on (b)(6) 2024 for hcg testing, prior to nexplanon placement for contraception.The patient provided a fresh urine sample.Three drops of urine were applied to the device and the results were read at 4 minutes yielding a positive hcg result.Confirmatory blood hcg testing was performed which yielded a negative result.No adverse events were reported.
 
Additional Manufacturer Narrative
D4 - expiration date: updated to provide the expiration date.D4 - primary udi number: updated to provide the udi number.H4 - device mfg date: updated to provide the manufacturing date.Investigation conclusion: retained devices from the reported lot number were tested with hcg-negative clinical urine samples.The results were read at 3 and 4 minutes and all devices yielded valid negative results.No false positive results were observed during in-house testing.The case details were reviewed along with the complaint history for the reported issue and no indications of a systemic issue were identified.Manufacturing batch record review did not uncover any relevant non-conformances and found that the lot met quality control specifications.Review of the risk management report for this product found that the reported issue is within the risk profile for this device; no new hazard has been identified.A root cause could not be determined from the available information as the reported issue was not replicated during testing of retention product.Complaints are tracked and trended on a monthly basis.Per the package insert: very low levels of hcg (less than 50miu/ml) are present in urine specimen shortly after implantation.However, because a significant number of first trimester pregnancies terminate for natural reasons, a test result that is weakly positive should be confirmed by retesting with a first morning urine specimen collected 48 hours later.A number of conditions other than pregnancy, including trophoblastic disease and certain non-trophoblastic neoplasms including testicular tumors, prostate cancer, breast cancer, and lung cancer, cause elevated levels of hcg.Therefore, the presence of hcg in urine specimen should not be used to diagnose pregnancy unless these conditions have been ruled out.The test provides a presumptive diagnosis for pregnancy.A confirmed pregnancy diagnosis should only be made by a physician after all clinical and laboratory findings have been evaluated.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ALERE HCG10/20 DEVICE (SERUM/URINE) 40T
Common Device Name
VISUAL, PREGNANCY HCG, PRESCRIPTION USE
Manufacturer (Section D)
ALERE SAN DIEGO, INC.
9942 mesa rim rd
san diego CA 92121
Manufacturer Contact
monika burrell
9942 mesa rim rd
san diego, CA 92121
8588052506
MDR Report Key19585753
Report Number2027969-2024-00082
Device Sequence Number7392269
Product Code JHI
UDI-Device Identifier10815845020123
UDI-Public(01)10815845020123(17)250925(10)0000788576
Combination Product (Y/N)N
Initial Reporter StateKS
Initial Reporter CountryUS
PMA/510(K) Number
K993203
Number of Events Summarized1
Summary Report (Y/N)N
Serviced by Third Party (Y/N)N
Reporter Type Manufacturer
Report Source Health Professional
Initial Reporter Occupation Other
Type of Report Initial,Followup
Report Date (Section B) 07/24/2024
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Operator of Device Health Professional
Device Expiration Date09/25/2025
Device Model NumberFHC-A202
Device Catalogue Number92215
Device Lot Number0000788576
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? No
Type of Report(Section G)Thirty-Day
Initial Date Received by Manufacturer 06/03/2024
Supplement Date Received by Manufacturer07/16/2024
Initial Report FDA Received Date06/21/2024
Supplement Report FDA Received Date07/24/2024
Was Device Evaluated by Manufacturer? (Y/N) No
Date Device Manufactured09/27/2023
Is the Device Labeled for Single Use? (Y/N) Yes
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Usage of Device Initial
Patient Sequence Number1
Patient Age38 YR
Patient SexFemale
-
-